Table 1 Clinical characteristics.
Case | Sex/age | Diagnosis | Int* (mon) | Prior malignancy | Peripheral blood | Treatment | Outcome | OS (mon) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WHO | FAB | Diagnosis | Treatment | Blast | WBC 109/L | Hgb g/dL | PLT 109/L | ||||||
1 | M/75 | AML-MRC | M0 | No | – | 33% | 2.8 | 9.6 | 107 | Decitabine, vosaroxin | Deceased | 0.9 | |
2 | M/62 | AML-MRC | M1 | No | – | 67% | 2.3 | 8.1 | 71 | Azacitidine, vorinostat | Deceased | 1.0 | |
3 | M/54 | AML-MRC | M1 | No | – | 0 | 0.1 | 7.9 | 21 | FLAG-IDA, guadecitabine | Deceased | 6.1 | |
4 | F/83 | AML-MRC | M1 | No | – | 20% | 1.3 | 8.6 | 163 | Venetoclax, decitabine | AWD | 4.5 | |
5 | F/65 | AML-MRC | M2 | 294 | Breast cancer | Surgery, tamoxifen | 3% | 1.1 | 7.9 | 115 | Guadecitabine SCT | ACR | (4) + 76 |
6 | F/34 | AML-MRC | M2 | 5 | MDS | Decitabine | 66% | 0.3 | 8.3 | 4 | ONC201 trial | Deceased | 0.4 |
7 | M/39 | AML-MRC | M1 | 7 | CMML-1 | Decitabine | 12% | 0.5 | 8.6 | 19 | Cladribine, idarubicin, cytarabine | AWD | 0.5 |
8 | M/75 | AML-MRC | M2 | 120 | MDS/MPN (JAK2 mutated) | Vidaza, decitabine | 17% | 15.4 | 9.0 | 56 | Chemo JAK2 inhibitor | Deceased | 3.1 |
9 | M/66 | AML-MRC | M2 | 76 | Prostate cancer | Radiation | 5% | 1.4 | 7.4 | 83 | 7 + 3 | Deceased | 12.5 |
10 | F/50 | AML-MRC (relapsed) | M1 | 38 | Uterine sarcoma AML | Surgery chemo (AML) | 12% | 0.9 | 7.2 | 10 | 7 + 3 | Deceased | 3.0 |
11 | F/74 | AML-MRC (relapsed) | M2 | 6 | AML | Chemo (AML) | 0 | 1.9 | 9.3 | 20 | NA | AWD | 2.0 |
12 | F/64 | t-AML | M6 | 140 | Breast cancer | Chemo | 1% | 6.1 | 7.8 | 13 | No detail | Deceased | 6.1 |
13 | M/65 | t-AML | M2 | 69 | PCM | Chemo | 0 | 0.8 | 8.2 | 13 | NA | AWD | 3.2 |
